Critical molecular abnormalities in high-grade serous carcinoma of the ovary

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

(2008) Joshua Z Press et al.   BMC CANCER

Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance

(2008) E. M. Swisher et al.   CANCER RESEARCH

A comprehensive modular map of molecular interactions in RB/E2F pathway

(2008) Laurence Calzone et al.   Molecular Systems Biology

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

(2008) Wataru Sakai et al.   NATURE

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance

(2007) R. SALANI et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER